Rifaximin for small intestinal bacterial overgrowth in patients without irritable bowel syndrome
Open Access
- 17 October 2014
- journal article
- research article
- Published by Springer Nature in Annals of Clinical Microbiology and Antimicrobials
- Vol. 13 (1) , 49
Abstract
Rifaximin is a minimally absorbed antibiotic with high luminal activity, used to treat various gastrointestinal diseases. Although rifaximin has been proposed as first line treatment for small intestinal bacterial overgrowth (SIBO), few data are available regarding its efficacy in non-IBS subjects. We aimed to assess the ability of rifaximin to normalize lactulose-H2 breath tests in non-IBS subjects with symptoms suggestive of SIBO. Consecutive non-IBS patients presenting with bloating and flatulence were prospectively recruited and submitted to lactulose-H2 breath testing (LBT). Patients who had a positive result were offered rifaximin 1200 mg daily for 10 days. Breath testing was repeated two weeks after treatment completion in all patients in order to assess for response. A total of 19 patients with a positive result received rifaximin and repeated the breath test (7 (36.8%) males, age 56.5 ± 17.6 years). The mean peak hydrogen excretion was 13.7 ± 2.8 and 10.3 ± 7.3 ppm at baseline and following rifaximin treatment, respectively (t = 1.98, p = 0.06). LBT normalized in 8/19 (42.1%) subjects. No patients reported symptom resolution. No adverse events were reported. Strengths include the study's prospective design. Limitations include the small sample size and open label design. Rifaximin was not effective in normalizing LBT in our cohort of non-IBS subjects with symptoms suggestive of SIBO.Keywords
This publication has 35 references indexed in Scilit:
- Review article: small intestinal bacterial overgrowth - prevalence, clinical features, current and developing diagnostic tests, and treatmentAlimentary Pharmacology & Therapeutics, 2013
- Performance Characteristics of qPCR Assays Targeting Human- and Ruminant-AssociatedBacteroidetesfor Microbial Source Tracking across Sixteen Countries on Six ContinentsEnvironmental Science & Technology, 2013
- How to Interpret Hydrogen Breath TestsJournal of Neurogastroenterology and Motility, 2011
- Double-Blind Randomized Controlled Trial of Rifaximin for Persistent Symptoms in Patients with Celiac DiseaseDigestive Diseases and Sciences, 2011
- High-dose rifaximin treatment alleviates global symptoms of irritable bowel syndromeClinical and Experimental Gastroenterology, 2011
- Double‐blind, Placebo‐controlled Antibiotic Treatment Study of Small Intestinal Bacterial Overgrowth in Children With Chronic Abdominal PainJournal of Pediatric Gastroenterology and Nutrition, 2011
- Rifaximin Therapy for Patients with Irritable Bowel Syndrome without ConstipationNew England Journal of Medicine, 2011
- Clinical trial: the combination of rifaximin with partially hydrolysed guar gum is more effective than rifaximin alone in eradicating small intestinal bacterial overgrowthAlimentary Pharmacology & Therapeutics, 2010
- Effect of Rifaximin on Intestinal Bacterial Overgrowth in Crohn's Disease as Assessed by the H2-Glucose Breath TestCurrent Medical Research and Opinion, 2000
- American Gastroenterological Association medical position statement: Guidelines for the evaluation and management of chronic diarrhea☆, ☆☆Gastroenterology, 1999